Citations 1
Cost per remission for mirikizumab versus ustekinumab for moderately to severely active ulcerative colitis treatment from the United States commercial payer perspective
Gulati, Ankit, Kane, Sunanda V. , Creveling, Thomas, Bires, Nicholas, Fisher, Deborah A. , Chanan, Neha, Koushik, Amit Kumar, Upadhyay, Navneet , Gulati, Ankit, Mittal, Neha
Journal of Medical Economics | May 12, 2025 | Volume: 28 | Issue: 1 | Pages: 709-718
